We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » GERMAN-BASED EKSA CITED FOR QS, MDR VIOLATIONS

GERMAN-BASED EKSA CITED FOR QS, MDR VIOLATIONS

July 13, 2006

ESKA Implants was issued a May 16 warning letter for quality system (QS) and medical device reporting deficiencies that were uncovered during a November 2005 inspection of the company's Lubeck, Germany, facility. The company manufactures total hip replacement prostheses.

Under the QS regulation, the agency cited the firm for not establishing adequate procedures for implementing corrective and preventive actions (CAPAs). Specifically, the agency said the firm's CAPA procedures do not contain sufficient detail for "analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product."

The CAPA procedures also did not provide enough detail for identifying the actions needed to prevent recurrence of those nonconformities, the FDA said.

ESKA also failed to adequately maintain procedures for identifying, documenting and validating design changes before implementing them, the warning letter says.

In addition, the firm did not maintain appropriate procedures for defining and documenting design outputs compared with design inputs. For example, the device master record (DMR) specifies that cobalt chromium-molybdenum alloy be used to manufacture cementless femoral stems. But the agency identified numerous specification differences between the DMR and the standard, according to the warning letter. ()a href="http://www.fdanews.com/ddl/33_27/" target=_blank>

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

  • 07Mar

    FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Consortium Gets EU Funding to Develop Continuous Blood Pressure Monitoring Device

  • FDA Approves GSK’s Oral Drug for Chronic Kidney Disease-Related Anemia

  • Aspivix’s Carevix Cleared to Reduce Pain, Bleeding in Gynecological Procedures

  • FDA Warns That Energy Supplement Contains Active Cialis Ingredient

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing